Literature DB >> 19178563

The role of titration schedule of topiramate for the development of depression in patients with epilepsy.

Marco Mula1, Dale C Hesdorffer, Michael Trimble, Josemir W Sander.   

Abstract

PURPOSE: To determine whether a fast titration schedule of topiramate (TPM) has different effects on the occurrence of depression, in relation to other risk factors for TPM-induced depression, including history of depression (HxDEP), febrile seizures (FS), and hippocampal sclerosis (HS).
METHODS: Using data from a large case registry of patients prescribed TPM, two models were constructed: Model 1 examined the independent effect of rapid TPM titration after separate adjustment for FS, HxDEP, and HS. Model 2 examined effect of the cooccurrence of rapid titration on the development of depression with each of these risk factors.
RESULTS: A total of 423 patients were included (51.8% females), mean age (SD) 35.5 (11.8) years, mean duration of epilepsy of 22.2 (11.5) years. Forty-four patients (10.4%) developed depression during TPM therapy. A rapid TPM titration was associated with 5-fold increased risk of depression that increased to 12.7-fold in the presence of both FS and rapid TPM titration, 23.3-fold in the presence of both HxDEP and rapid TPM titration, and 7.6-fold in the presence of both HS and rapid TPM titration schedule.
CONCLUSIONS: Our study suggests that a rapid titration schedule is associated with an increased risk of developing depression during TPM therapy. HxDEP and FS are major contraindications to the use of a rapid titration, with a 23.3-fold and 12.7 fold increased risk, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19178563     DOI: 10.1111/j.1528-1167.2008.01799.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  14 in total

Review 1.  Depression in epilepsy: a critical review from a clinical perspective.

Authors:  Christian Hoppe; Christian E Elger
Journal:  Nat Rev Neurol       Date:  2011-07-12       Impact factor: 42.937

Review 2.  Suicidality in epilepsy and possible effects of antiepileptic drugs.

Authors:  Marco Mula; Gail S Bell; Josemir W Sander
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 3.  Management of psychiatric and neurological comorbidities in epilepsy.

Authors:  Andres M Kanner
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

Review 4.  Epilepsy and Psychiatric Comorbidities: Drug Selection.

Authors:  Marco Mula
Journal:  Curr Treat Options Neurol       Date:  2017-10-19       Impact factor: 3.598

Review 5.  Tolerability of new antiepileptic drugs: a network meta-analysis.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Filippo Sean Giorgi; Valentina Franco; Sara Gasparini; Umberto Benedetto
Journal:  Eur J Clin Pharmacol       Date:  2017-04-04       Impact factor: 2.953

Review 6.  Topiramate and cognitive impairment: evidence and clinical implications.

Authors:  Marco Mula
Journal:  Ther Adv Drug Saf       Date:  2012-12

7.  Can antiepileptic drugs unmask a susceptibility to psychiatric disorders?

Authors:  Andres M Kanner
Journal:  Nat Clin Pract Neurol       Date:  2009-03

Review 8.  Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2).

Authors:  Amos D Korczyn; Steven C Schachter; Martin J Brodie; Sarang S Dalal; Jerome Engel; Alla Guekht; Hrvoje Hecimovic; Karim Jerbi; Andres M Kanner; Cecilie Johannessen Landmark; Pavel Mares; Petr Marusic; Stefano Meletti; Marco Mula; Philip N Patsalos; Markus Reuber; Philippe Ryvlin; Klára Štillová; Roberto Tuchman; Ivan Rektor
Journal:  Epilepsy Behav       Date:  2013-06-10       Impact factor: 2.937

9.  Psychopathology in pediatric epilepsy: role of antiepileptic drugs.

Authors:  Rochelle Caplan
Journal:  Front Neurol       Date:  2012-12-07       Impact factor: 4.003

Review 10.  Depressogenic effects of medications: a review.

Authors:  Christopher M Celano; Oliver Freudenreich; Carlos Fernandez-Robles; Theodore A Stern; Mario A Caro; Jeff C Huffman
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.